Type 2 diabetes guidelines: keeping Scotland on the map

Gemma Currie · Keith Brown · Robin Harbour ·
John Petrie

Received: 24 June 2013 / Accepted: 26 June 2013 / Published online: 4 August 2013
© Springer-Verlag Berlin Heidelberg 2013

Keywords Diabetes · Guidelines · SIGN 116 · Treatment · Type 2

To the Editor: We read with interest the review article by Mühlhauser and Meyer [1] in the June 2013 issue. However, we would like to highlight that incomplete information was given within Table 1, which summarises existing reviews of type 2 diabetes guidelines, including those by Bennett et al [2] and the German Institute for Quality and Efficiency in Health Care [3].

The table correctly states that in the published review by Bennett and colleagues [2] the Scottish Intercollegiate Guidelines Network 2010 guideline (SIGN 116) [4] was not included. However, we would like to highlight that the authors later provided a substantial erratum in which SIGN 116 was included [5]. This was in response to a letter from some of the present authors [6].

In the erratum, SIGN 116 scored 97.6% for rigour of development and 100% for editorial independence, making it one of the highest quality international diabetes guidelines available.

Duality of interest John Petrie has provided consultancy or served on trial committees for pharmaceutical companies manufacturing products for the treatment of diabetes, including Bristol-Myers Squibb Pharma, Daaichi Sankyo, GlaxoSmithKline, Novo Nordisk, Pfizer, Roche and Takeda.

Contribution statement All authors were responsible for the conception and design of the manuscript, drafting the article and revising it critically for important intellectual content. All authors approved the version to be published.

References

1. Mühlhauser I, Meyer G (2013) Evidence base in guideline generation in diabetes. *Diabetologia* 56:1201–1209
2. Bennett WL, Odelola OA, Wilson LM et al (2012) Evaluation of guideline recommendations on oral medications for type 2 diabetes mellitus: a systematic review. *Ann Intern Med* 156:27–36
3. IQWiG (2011) Systematic guideline search and appraisal, as well as extraction of new and relevant recommendations, for the DMP “diabetes mellitus type 2”. IQWiG Reports – Commission no. V09-04 (German, executive summary in English). IQWiG, Cologne. Available from www.iqwig.de/download/V09-04_Executive_Summary_Guideline-search-and-appraisal-for-the-DMP-diabetes-mellitus-type-2.pdf, accessed 13 June 2013
4. Scottish Intercollegiate Guidelines Network (2010) Management of diabetes: a national clinical guideline. Guideline no. 116. Edinburgh, Scotland: Scottish Intercollegiate Guidelines Network. Available from www.sign.ac.uk/guidelines/fulltext/116, accessed 13 June 2013
5. Bennett W, Odelola O, Wilson LM (2012) Response. Evaluation of guidelines on diabetes medication. *Ann Intern Med* 156:753–754
6. Brown K, Harbour R, Petrie J (2012) Evaluation of guidelines on diabetes medication. *Ann Intern Med* 156:752

G. Currie (✉) · J. Petrie
BHF Glasgow Cardiovascular Research Centre, University of
Glasgow, 126 University Place, Glasgow G12 8TA, UK
e-mail: gemma.currie@glasgow.ac.uk

K. Brown · R. Harbour
Scottish Intercollegiate Guidelines Network, Edinburgh, UK